Back to search

Article

The effects of rasagiline on cerebral glucose metabolism, cognition, and tau in a double-blind, placebo-controlled Phase II clinical trial in Alzheimer’s dementia

2020-07-02

Abstract excerpt

<title>Abstract</title> <p>BackgroundA Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a MAO-B inhibitor, in mild to moderate Alzheimer’s disease (AD). The primary objective was to determine if 1 mg of rasagiline daily for 24 weeks is associated with improved regional brain metabolism (fluoro-2-deoxyglucose positron emission tomography (FDG PET)) comp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f967fb50-650f-5437-9149-a25a524aa240
DOI
10.21203/rs.3.rs-39380/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The effects of rasagiline on cerebral glucose metabolism, cognition, and tau in a double-blind, placebo-controlled Phase II clinical trial in Alzheimer’s dementiaDOI 10.21203/rs.3.rs-39380/v1
Treatment effects of pharmacotherapy and non-pharmacotherapy of Alzheimer dementia: A systematic review overview and updated network meta-analysis.Semantic proximity
Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease PatientsSemantic proximity
Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.Semantic proximity
Combined Metabolic Activators Improves Cognitive Functions in Alzheimer’s DiseaseSemantic proximity
An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.Semantic proximity
A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer’s disease (ART-AD)Semantic proximity
Imaging brain class I histone deacetylase changes in the Lewy body dementias and Parkinson’s diseaseSemantic proximity
Geographic variation in dementia-related adverse events associated with sacubitril/valsartan: Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Safety, tolerability and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD) trialSemantic proximity
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trialSemantic proximity
Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trialsSemantic proximity
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.Semantic proximity
Select a neighboring publication to make it the new centre.